PM ET. Please refresh the page if you do not see a player above at that time.] CNBC’s ETF Edge is dedicated to the ...

The tech-heavy Nasdaq 100 is the best performer but more risk-averse investors may prefer the more broadly diversified S&P 500.

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

DeepSeek is a Chinese AI research lab founded in 2023 by Liam Wenfeng, who has also founded the hedge fund that backed DeepSeek.

Big Tech's rapid earnings growth finally slowing has been a risk to the market strategists have been talking about for more ...